How common is hypothyroidism with fruquintinib in patients with metastatic colorectal cancer?

Hypothyroidism (including increased blood thyroid-stimulating hormone) was very common with fruquintinib in metastatic colorectal cancer: 32.4% among 911 pooled-study patients and 31.5% versus 2.8% with placebo in randomised trials, mostly mild to moderate, with grade ≥3 events in 0.3% of fruquintinib-treated patients.